Načítá se...
EGFR-Targeted Therapies in the Post-Genomic Era
Over ninety percent of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylin...
Uloženo v:
| Vydáno v: | Cancer Metastasis Rev |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693744/ https://ncbi.nlm.nih.gov/pubmed/28866730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-017-9687-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|